Groupe Roski
VC Fund
Montréal, Canada
Groupe Roski is a private investment company that has been involved in venture capital since 2013 with companies that improve the quality of life and the environment for individuals.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Groupe Roski invests in
Stages Groupe Roski invests in
Countries Groupe Roski invests in
Round sizes
Round size
- Seed
- $1.5M–$3.9M
- Series A
- $14M–$20M
Investment Focus
Industry
- Health Care 5 (36%)
- Biotechnology 5 (36%)
- Medical 2 (14%)
- Life Science 2 (14%)
- Medical Device 2 (14%)
Stage
- Seed 7 (50%)
- Series A 3 (21%)
- Funding Round 2 (14%)
- Angel 1 (7%)
- Corporate Round 1 (7%)
Country
- Canada 13 (93%)
- United States 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Spiderwort is developing a novel biomaterial that will offer new avenues in regenerative medicine. We are using plant derived cellulose to create a variety of scaffold architectures. Currently, we are in the pre-clinical stage of this product and our promising results demonstrate that this new biomaterial is highly biocompatible and induceangiogenesis (blood vessel generation inside the scaffold). | $2.5M / Seed / May 27, 2020 | ||
| Marmax deals with residential and commercial construction, renovation and roofing. | $1.5M / Seed / Nov 08, 2019 | ||
| Groupe Evex deals with the commercial real estate projects. | $2.3M / Seed / Nov 08, 2019 | ||
| Montreal-based My Intelligent Machines (MIMs) is a leader in artificial intelligence and systems biology. MIMs provides Biopharma companies with easy-to-implement and interactive augmented intelligence systems, allowing for accurate biological simulations at early drug development stages, to assist life scientists in the development of preciselytargeted and personalized therapies. | $2.6M / Seed / Sep 05, 2019 | ||
| Evey platform can alert residents in case of a leak, escalate with employees without taking action, or directly cut off the water valve thanks to its water damage detectors. It increases the autonomy of residents by optimizing their safety and well-being in apartments while reducing operating costs. | Seed / May 08, 2019 | ||
| Laurent Pharmaceuticals is a private biopharmaceutical company developing a clinical-stage, orally-active drug candidate. The company has a clinical-stage drug development program (LAU-7b) that addresses the compromised immune-inflammatory response in Cystic Fibrosis (CF), a critical but still enigmatic pathogenic pathway leading to pulmonaryinsufficiency in CF patients.Laurent Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec. | Venture - Series Unknown / Oct 25, 2018 | ||
| Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle. | $13.8M / Series A / Sep 18, 2018 | ||
| 4C Medical Technologies is a medical device company that develops minimally invasive therapies for structural heart disease. It preserves the native mitral valve and left ventricle, eliminating known issues associated with transcatheter mitral valve replacement technologies that rely on placement and fixation in the native mitral annulus and leftventricle. | $17M / Series A / Sep 10, 2018 | ||
| impak Finance connects savers and investors with entrepreneurs and companies working for a sustainable transformation. | $1.1M / Angel / Aug 16, 2018 | ||
| We’re a bioengineering company that's reducing the massive environmental footprint of the CBD market through precision fermentation. And our technology never touches a plant. CBD is a global $12Bn consumer market and Hyasynth's precision fermentation platform eliminates wasteful plant cultivation and decreases the carbon impact by morethan 97%. Hyasynth is the world's only bioengineering company with a scalable, fermentation process for CBD that is cost-efficient and regulatory-compliant. | $7.8M / Corporate Round / May 24, 2018 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Groupe Roski invest in?
Groupe Roski invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 14 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Groupe Roski's check size?
Groupe Roski typically joins rounds of $1.5M–$3.9M at Seed and $14M–$20M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Groupe Roski participates in.
When did Groupe Roski last invest?
The most recent investment recorded for Groupe Roski closed in May 2020. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
